Back to top

Press Releases

Zacks Equity Research

The Zacks Analyst Blog Highlights: Deutsche Bank, Apple, Therapeutics, Allergan and Gilead Sciences


Trades from $3

For Immediate Release

Chicago, IL – September 26, 2016 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Deutsche Bank AG (DB), Apple Inc (AAPL), Therapeutics, Inc (TBRA), Allergan plc (AGN) and Gilead Sciences Inc. ( GILD).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Friday’s Analyst Blog:

Dow 30 Stock Roundup

The Dow experienced a strong week of gains, buoyed by the Fed’s decision to leave rates unchanged in September. Japan’s central bank’s decision to control the yield curve also provided a flip to stocks. Additionally, gains arising from developments related to major healthcare deals also lifted benchmarks. Economic data was mixed in nature while oil price movement continued to be volatile.

Last Week’s Performance

The Dow decreased 0.5% last Friday following declines in bank stocks on news that Deutsche Bank AG ( DB) might have to pay a fine of $14 billion to settle a mortgage-backed securities case. Moreover, concerns over crude oversupply weighed on energy stocks, which also had a negative impact on key U.S. indexes.

Additionally, uncertainty remained over the timing of a rate hike ahead of the Fed policy meeting. Meanwhile, the CPI increased 0.2% in August, higher than the consensus estimate of 0.1%.

The Dow gained 0.2% over last week. Apple Inc’s (AAPL) shares jumped 11.4% for the week, its best rise since October 2011, after the tech-giant experienced strong demand for the new iPhone 7. Meanwhile, rate hike worries continue to inject uncertainty into the markets.

The Dow This Week

The index ended Monday mostly unchanged as investors refrained from making big bets ahead of the two-day policy meetings of the Fed and Bank of Japan (BOJ). Increase in oil prices and strong rise in home-builder confidence had a positive impact on key U.S. indexes. During the weekend, military conflicts in Libya weighed on its crude exports.

Moreover, Venezuelan President Nicolas Maduro said that both OPEC and non-OPEC countries are nearing a deal to control crude production. Both these factors boosted crude prices. According to the National Association of Home Builders and Wells Fargo, builder sentiment touched its highest level since Oct, 2015.

The index increased 0.1% on Tuesday ahead of the two-day policy meetings of the Fed and the BOJ. Inventors eagerly awaited any major policy decisions from the two central banks. Moreover, gains in healthcare stocks offset declines in energy stocks. Tobira Therapeutics, Inc’s (TBRA) shares jumped 720.9% after Allergan plc ( AGN) decided to acquire the company for $1.7 billion.

Tobira develops products which are used to treat a common liver disease called nonalcoholic steatohepatitis, or NASH. Following this development, shares of Gilead Sciences Inc. (GILD), which also develops drugs to treat NASH, rose 3.5%.

While acquisition news boosted the healthcare sector, crude oversupply concerns weighed on energy stocks. Oil prices closed mixed after Colonial Pipeline said that worries over supply disruptions from Gulf Coast refiners have faded as the gasoline line is expected to restart functioning.

The index gained 0.9% on Wednesday after the Fed kept key interest rates unchanged. The FOMC in its policy statement said that argument for a rate hike “has strengthened,” but the central bank waited for “further evidence of continued progress” before raising rates. Although, the lack of a rate hike in September boosted markets, some of its gains were pared following rising expectations of a rate hike in December.

The BOJ’s surprise move to control the yield curve also had a positive impact on both the global and domestic markets. Further, strong decline in crude inventories boosted oil prices, which in turn led gains for energy stocks.

Fed’s decision to keep interest rates unchanged continued to lead the Dow higher on Thursday and the blue-chip index gained 0.5%. However, Fed Chairwoman Janet Yellen’s comments fueled December rate hike chances even further. Meanwhile, sales of existing homes fell 0.9% in August while the Leading Indicators Index decreased 0.2% in September.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Follow us on Twitter:

Join us on Facebook:

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact
Zacks Investment Research

800-767-3771 ext. 9339

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.